Skip to content
AnalystLens

Cencora, Inc. Annual Report, Year Ended Sep 30, 2003

Filing Date
Filed December 19, 2003
Period End
September 30, 2003
Security
COR
In the record · 2016–202610-K1010-Q338-K184

COR filed 10 annual reports (10-K), 33 quarterly reports (10-Q) and 184 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jan ’18Jan ’18
  2. Impairment8-K · Jan ’20Jan ’20
  3. Leadership change8-K · Aug ’21Aug ’21
  4. FY2025 annual report10-K · Nov ’25Nov ’25

01—Abstract

Summary

Summary of the 10-K filed December 19, 2003. Cited figures are marked; the original filing is the authoritative source.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported strong performance for the fiscal year ended September 30, 2003.

The company experienced a significant 13% increase in operating revenue, reaching $45.5 billiona, driven primarily by its Pharmaceutical Distribution segment. This growth was supported by favorable industry trends such as an aging population and the introduction of new pharmaceuticals. The company also continued its strategic growth through several key acquisitions, including Bridge Medical, US Bioservices Corporation, and Anderson Packaging Inc., enhancing its service offerings and market position.

Despite a slight decrease in gross profit margin to 4.93% due to competitive pricing and changes in customer mix, AmerisourceBergen successfully improved operating income by 23% to $883.1 millionb. This was achieved through operational efficiencies, cost reductions stemming from merger integration, and a focus on lowering its operating expense ratio. The company also maintained its quarterly cash dividend, signaling confidence in its financial stability and future prospects.

02—Key points

Key Highlights

  1. Operating revenue increased by 13% to $45.5 billion for the fiscal year ended September 30, 2003.
  2. Operating income grew by 23% to $883.1 million, demonstrating improved profitability.
  3. The company completed several strategic acquisitions during the year, including Bridge Medical, US Bioservices Corporation, and Anderson Packaging Inc., to expand its service capabilities.
  4. Gross profit margin slightly decreased to 4.93% from 5.03% in the prior year, attributed to customer mix changes and competitive pressures.
  5. Distribution, selling, and administrative expenses as a percentage of revenue decreased to 2.98% from 3.19%, reflecting operational efficiencies.
  6. The company continued to pay quarterly cash dividends of $0.025 per share.
  7. AmerisourceBergen is actively consolidating its distribution network, aiming to reduce the number of facilities from 51 to 30 over the next three to four years through the 'Optimiz' program.

03—Questions

Frequently Asked Questions

  1. What is Cencora's (formerly AmerisourceBergen) primary business?

    Cencora is a leading wholesale distributor of pharmaceutical products and provides related healthcare services to healthcare providers and pharmaceutical manufacturers. It also serves patients directly through various channels.

  2. How did the company's revenue perform in fiscal year 2003?

    For the fiscal year ended September 30, 2003, Cencora reported a significant increase in operating revenue, up 13% to $45.5 billion, primarily driven by its Pharmaceutical Distribution segment.

  3. What key strategic initiatives did the company undertake during the fiscal year?

    The company pursued several strategic initiatives, including the acquisition of Bridge Medical, US Bioservices Corporation, and Anderson Packaging Inc. to broaden its service offerings. It also continued its 'Optimiz' program to consolidate its distribution network, aiming for greater efficiency.

  4. What is the company's outlook regarding profitability and dividends?

    The company demonstrated improved profitability with a 23% increase in operating income. It also maintained its quarterly cash dividend, indicating management's confidence in its financial health and future performance.

04—Continue

← View all 10-K filings